scholarly journals Effectiveness and safety of secukinumab in patients with moderate-to-severe plaque psoriasis – a real life retrospective study

2020 ◽  
Author(s):  
Katarzyna Galica ◽  
Aleksandra Lesiak ◽  
Magdalena Ciążyńska ◽  
Marcin Noweta ◽  
Igor Bednarski ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Plaque Psoriasis ◽  
Real Life ◽  
Severe Plaque Psoriasis

Adalimumab in severe plaque psoriasis of childhood: A multi‐center, retrospective real‐life study up to 52 weeks observation

2019 ◽  
Vol 32 (6) ◽  
Author(s):  
Vito Di Lernia ◽  
Luca Bianchi ◽  
Cristina Guerriero ◽  
Luca Stingeni ◽  
Paolo Gisondi ◽  
...  
Keyword(s):  
Plaque Psoriasis ◽  
Real Life ◽  
Severe Plaque Psoriasis ◽  
Life Study ◽  
Real Life Study

scholarly journals Centralised Biological Therapy Registry for Moderate to Severe Plaque Psoriasis – Overview and Methodology

2016 ◽  
Vol 16 (1) ◽  
pp. 36-48
Author(s):  
R Sutka ◽  
J Pec ◽  
T Pecova
Keyword(s):  
Plaque Psoriasis ◽  
Biological Therapy ◽  
Treatment Guidelines ◽  
Safety Data ◽  
Real Life ◽  
Developed Countries ◽  
Medical Intervention ◽  
Added Value ◽  
Severe Plaque Psoriasis ◽  
Set Up

Abstract The introduction of new pharmacotherapy entities in the last decade accentuate the necessity to set up treatment guidelines based on real life evidence. Randomized controlled trials remain golden standard of a research. Data derived from studies aiming on daily clinical practice should bring needed, added value. Disease prevalence growth, due to increased life expectancy, better diagnostic procedures and earlier medical intervention, as well as ever growing demand for highly priced, sophistically produced drugs put stress on healthcare budgets even in developed countries. Large databases commonly called - therapy registries are implemented to collect data on therapy effectivity in terms of effectiveness, safety and patient long-term on therapy survival. Registries importance rose together with biological therapies introduction. New in class molecules entered the market conditionally being obliged to provide additional e.g. safety data. Such procedures require involvement of many different professionals, e.g. physicians, professional medical bodies, IT experts, database administrators, statisticians and government institutions. Paper based, followed by computer based forms were distributed among physicians to collect these data. eHealth technologies provide physicians with centralized, more intuitive applications. The particularities of different diagnosis caused great variations within each specific registry launched. Important information was missing since they were pointed out as optional and many were redundant causing frustration among physicians due to inadequate administrative workload. The main objective of this work was to set up the therapy registry standards and procedures. Methodology of „ideal“ moderate to severe plaque psoriasis biology therapy registry development, introduction, administration and evaluation was prepared to assist any government institution or professional body when planning registry deployment. Electronic application based on widely used MS Excel platform was developed and installed in the biological therapy centers as a standalone application for the pilot use.

scholarly journals Erratum: Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting

2021 ◽  
Vol 10 ◽  
pp. 1-1
Author(s):  
Martina Burlando ◽  
Riccardo Castelli ◽  
Emanuele Cozzani ◽  
Aurora Parodi
Keyword(s):  
Plaque Psoriasis ◽  
Real Life ◽  
Severe Plaque Psoriasis ◽  
The Real ◽  
Real Life Setting

scholarly journals Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting

2021 ◽  
Vol 10 ◽  
pp. 1-4
Author(s):  
Martina Burlando ◽  
Riccardo Castelli ◽  
Emanuele Cozzani ◽  
Aurora Parodi
Keyword(s):  
Plaque Psoriasis ◽  
Real Life ◽  
Severe Plaque Psoriasis ◽  
The Real ◽  
Real Life Setting

scholarly journals In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis

2019 ◽  
Vol 20 (2) ◽  
pp. 173-182 ◽  
Author(s):  
Marco Galluzzo ◽  
Simone D’Adamio ◽  
Dionisio Silvaggio ◽  
Paolo Lombardo ◽  
Luca Bianchi ◽  
...  
Keyword(s):  
Plaque Psoriasis ◽  
Real Life ◽  
Severe Plaque Psoriasis ◽  
Life Analysis
Sign in / Sign up

Export Citation Format

Share Document